Aggregation of α-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine

Acta Neuropathologica

Volumn 115, Issue 2, 2008, Pages 193-203

  Burke, William J ^a   Kumar, Vijaya B ^a,b   Pandey, Neeraj ^c   Panneton, W Michael ^d   Gan, Qi ^d   Franko, Mark W ^a   O'Dell, Mark ^c   Li, Shu Wen ^a   Pan, Yi ^a   Chung, Hyung D ^a   Galvin, James E ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

Synuclein; 3,4 Dihydroxyphenylacetaldehyde; Dopamine metabolite; Parkinson's disease

Indexed keywords

3,4 DIHYDROXYPHENYLACETALDEHYDE; ACETALDEHYDE; ALPHA SYNUCLEIN; DOPAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONFOCAL MICROSCOPY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWY BODY; NERVE CELL INHIBITION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; SUBSTANTIA NIGRA; WESTERN BLOTTING;

3,4-DIHYDROXYPHENYLACETIC ACID; ALPHA-SYNUCLEIN; ANIMALS; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; DOPAMINE; IMMUNOHISTOCHEMISTRY; LEWY BODIES; MICROSCOPY, CONFOCAL; MONOAMINE OXIDASE; NEURONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 38149073317     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-007-0303-9     Document Type: Article

References (49)

1. Arasate M, Mitra S, Schweitzer ES, Segal MR (2004) Inclusion body formation reduces levels of mutant huntingtin and risk of neuronal death. Nature 431:805-810
2. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces feature of Parkinson's disease. Nature Neurosci 3:1301-1306
3. Blashko H (1952) Amine oxidase and amine metabolism. Pharmacol Rev 4:415-453
4. Burke WJ (2003) 3,4-Dihydroxyphenylacetaldehyde: A potential target for neuroprotective therapy in Parkinson's disease. Current Drug Targets. CNS Neurol Disord 2:143-148
5. Burke WJ, Li SW, Anwar M, Glickstein SB, Ruggiero DA (2001) Catecholamine-derived aldehyde induces apoptosis in adrenergic neurons in rostral ventral lateral medulla. Brain Res 891:218-227
6. Burke WJ, Li SW, Chung HD, Ruggiero DA, Kristal BS, Johnson EM, Lampe P, Kumar VB, Franko M, Zahm DS (2004) Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: Role in neurodegenerative diseases. Neurotoxicology 25:101-115
7. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS (2003) Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res 989:205-213
8. Burke WJ, Schmitt CA, Gillespie KN, Li SW (1996) 3,4-Dihydroxyphenylglycolaldehyde, the MAO-A metabolite of norepinephrine, is selectively toxic to differentiated rat pheochromocytoma cells. Brain Res 772:232-235
9. Cappai R, Leck S-L, Tew DJ, Williamson NA, Smith DP, Galatis D, Sharples RA, Curtain CC, Ali FE, Cherney RA, Culvenor JG, Bottomley SP, Masters CL, Barnham KJ, Hill AF (2005) Dopamine promotes α-synuclein aggregation into SDS-resistant soluble oligomers via a distinct folding pathway. FASEB J 19: 1377-1396
10. Coleman P, Federoff H, Kurlan R (2004) A focus on the synapse for neuroprotection in Alzheimer's disease and other dementias. Neurology 63:1155-1162
11. Conway KA, Rochet JC, Bieganski RM, Lansbury PT (2001) Kinetic stabilization of the α-synuclein protofibril by a dopamine α-synuclein adduct. Science 292:1346-1349
12. Dawson TM, Dawson VL (2003) Molecular pathways of degeneration in Parkinson's disease. Science 302:819-821
13. Fahn S (1997) Levo-dopa-induced neurotoxicity. CNS Drugs 8:276-393
14. Filloux F, Townsend JJ (1993) Pre- and postsynaptic neurotoxic effects demonstrated by intrastriatal injection. Exp Neurol 119:79-88
15. Galvin JE (2006) Interaction of alpha-synuclein and dopamine metabolites in pathogenesis of Parkinson's disease: A case for selective vulnerability of substantia nigra. Acta Neuropathol 112:115-126
16. Galvin JE, Lee VM, Trojanowski JD (2001) Synucleinopathies: Clinical and pathological implications. Arch Neurol 58:186-190
17. Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch FE, Krafft GA, Klein WL (2003) Alzheimer's disease-affected brain: Presence of oligomeric AB ligands (ADDLS) suggest a molecular basis for reversible memory loss. Proc Natl Acad Sci USA 100:10417-10422
18. Greenamyre JT, Hastings TG (2004) Parkinson's - divergent causes, convergent mechanisms. Science 304:1120-1122
19. Hashimoto M, Hsu LJ, Sisk A, Xia Y, Taked A, Sundmo M, Masliah E (1998) Human recombinant NACP/α-synuclein is aggregated and fibrillated in vitro: Relevance for Lewy body disease. Brain Res 99:301-306
20. Hirsch EC, Faucheux B, Damier P, Mouatt-Prigent A, Agid Y (1997) Neuronal vulnerability in Parkinson's disease. J Neural Transm 50:79-88
21. Hornykiewicz O (1996) Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 18:925-965
22. Jellinger K (1987) Overview of morphological changes in Parkinson's disease. J Adv Neurol 45:1-18
23. Kristal BS, Conway AD, Brown AM, Jain JC, Ulluci PA, Li SW, Burke WJ (2000) Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria. Free Radic Bio Med 30:24-931
24. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genet 18:106-108
25. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola K (1998) Diffusible, nonfibrillar ligands derived from AB 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 95:6448-6453
26. Lamensdorf I, Eisenhofer G, Harvery-White J, Nechustan A, Kirk K, Kopin IJ (2000) Dihydroxyphenylacetaldehyde potentiates the toxic effects of metabolic stress in PC 12 cells. Brain Res 868:191
27. Lee FJS, Liu F, Pristupa ZB, Niznik HB (2001) Direct binding and functional coupling of α-synuclein to dopamine transporters accelerate dopamine-induced apoptosis. FASEB J 15:916-926
28. Li HT, Lin DH, Luo XY, Zhang F, Ji LN, Du HN, Hi J, Zhou JW, Hu HY (2005) Inhibition of α-synuclein fibrillation by dopamine analogs via reaction with amino groups of α-synuclein: Implication for dopaminergic neurodegeneration. FEBS J 272:3661-3672
29. Li SW, Burke WJ (1998) Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde. Bioorg Chem 26:45-50
30. Li SW, Li HT, Minteer S, Burke WJ (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: Possible role in Parkinson's disease pathogenesis. Brain Res 93:1-7
31. Mandel S, Grunblatt E, Riederer P, Amariglio N, Hirsch JJ, Rechari G, Youdim MBH (2007) Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin proteosome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann NY Acad Sci 1053:356-375
32. Mazzulli JR, Mishizen AJ, Giasson BJ, Lynch DR, Thomas SA, Nakashima A, Nagatsu T, Ota A, Ischiropoulos H (2006) Cytosolic catechols inhibit α-synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J Neurosci 26:10068-10078
33. Miller DW, Hague SM, Clairmon J, Baptista M, Gwinn-Hardy K, Cokson MR, Singleton AB (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835-1838
34. Nagatsu T, Sawada M (2006) Cellular and molecular mechanisms of Parkinson's disease: Neurotoxins, causative genes and inflamatory cytokines. Cell Mol Neurobiol 26:779-800
35. Narhi L (1999) Both familial Parkinson's disease mutations accelerate α-synuclein aggregation. J Biol Chem 274:9843-9846
36. Norris EH, Giasson BI, Hodara R, Xu S, Trojanowski JQ, Ischiropoulos H, Lee VM (2005) Reversible inhibition of α-synuclein fibrillizationation by dopaminochrome-mediated conformational alterations. J Biol Chem 280:21212-21219
37. Osterova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B (2000) The A53T α-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054
38. Paik SR, Shin HJ, Lee JH (2000) Metal catalyzes oxidation of α-synuclein in the presence of copper (II) and hydrogen peroxide. Arch Biochem Biophys 378:269-277
39. Pandey N, Schmidt RE, Galvin JE (2006) Mutations of KTKEGV repeat region of alpha-synuclein promotes aggregation in cultured cells. Expl Neurol 187:1515-1520
40. Parkinson J (1817) An Essay on Shaking Palsy
41. Polymeropoulos MD, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Stenroos ES, Chandraskharappa s, Athanassiadou H, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Dilorio G, Golbe LI, Nussbaum RL (1997) Mutation in α-synuclein gene identified in families with Parkinson's disease. Science 275:2045-2047
42. Sawada H, Khono R, Kihara T, Izumi Y, Sakka N, Ibi M, Nakanishi M, Nakamizo T, Yamakawa K, Shibasaki H (2004) Proteasome mediates dopaminergic neuronal degeneragion and its inhibition causes alpha-synuclein inclusions. J Biol Chem 279:10710-10719
43. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827
44. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goerdert M (1997) α-Synuclein in Lewy bodies. Nature 388:839-840
45. Swerdlow RH, Parks JK, Davis JN, Cassarino BS, Trimmer PA, Currie LJ, Dougherty S, Bridges WS, Bennet JP, Wooten GF, Parker DW (2004) Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol 44:873-881
46. Volles MJ, Lansbury PT (2002) Vesicle permeabilization by protofibrillar α-synuclein: Comparison of wild type with Parkinson's disease-linked mutants and insights in the mechanism. Biochemistry 41:4595-4602
47. Volles MJ, Lee SJ, Rochet JC, Schtelerman MD, Ding JT, Kessler JC, Lansbury PT (2001) Vesicle permeabilization by protofibrillar α-synuclein: Implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40:7812-7819
48. Xu J, Kao SY, Song W, Jin LW, Yankner BA (2002) Dopamine-dependent neurotoxicity of α-synuclein: A mechanism for selective neurodegeneration in Parkinson's disease. Nat Med 8:600-606
49. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros RB, Ampuero I, Vidal L, Hoeniaka J, Rodríguez O, Atares B (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173